PTGS2 and melanoma: In murine melanoma models, pharmacologic COX inhibition with aspirin or celecoxib markedly potentiated the antitumor activity of αPD-1 antibody, indicating that targeting the COX-2/PGE2 pathway may serve as an effective adjunct to ICI therapy [37].